TERT mutations may be a potential biomarker for anti‐CTLA4 treatment, but not programmed cell death‐1 (PD‐1)/programmed cell death‐L1 (PD‐L1) blockade and combination treatment across pan‐cancer types. This evidence concerns the gene PDCD1 and cancer.